Celgene (CELG) estimates, price target were boosted at Cantor Fitzgerald. Shares are now seen reaching $156. Estimates were also upped, as the company raised its guidance, Cantor said. Buy rating.
CME Group (CME) numbers were raised at Citigroup. Estimates were increased on better interest rate volatility and capital market activity, said Citigroup. Price target goes to $82.
Dana Holdings (DAN) estimates were reduced at UBS. Estimates were reduced to reflect fewer share buybacks, said UBS. Price target is $24.
Embraer (ERJ) estimates were reduced at UBS. Estimates were reduced to reflect weaker margin performance and higher R&D expenses, said UBS. Price target is $40.Gilead Sciences (GILD) numbers were raised at UBS. Estimates were raised to now include preliminary idelalisib estimates, said UBS. Price target is $72. General Motors (GM) numbers were increased at Citigroup. Estimates were raised on the second-quarter beat, confidence in pickup truck pricing and lower interest expense, said Citigroup. Price target goes to $45. Hershey (HSY) estimates, price target were increased at BMO Capital. Estimates were raised through 2014. Higher sales are driving margin expansion, BMO Capital said. Market Perform rating and new $95 price target. McGraw Hill (MHFI) numbers were raised at UBS. Estimates were raised to reflect the second-quarter beat and higher margins in 2014, said UBS. Price target is now $66. Maxim Integrated numbers were cut at Citigroup. Estimates were cut on low-quality industrial performance and Samsung retrograde risk, said Citigroup. Price target goes to $27. Precision Castparts numbers were cut at Citigroup. Estimates were cut to reflect near-term weakness in commercial OE engine demand, said Citi. Price target goes to $266. Teradyne (TER) numbers were lowered at UBS. Future earnings estimates were lowered based on lower growth expectations in the wireless test business, UBS said. Price target was reduced to $20. T-Mobile (TMUS) numbers were raised at UBS. Estimates were raised as JUMP is now expected to provide an incremental boost to EBITDA, said UBS. Price target is now $28. WellPoint (WLP) numbers were raised at UBS. Estimates were raised on a strong quarter and reduced costs, said UBS. The new price target is $87. >To submit a news tip, email: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts